Introduction
Of all the areas where trademark law intersects with public welfare, none is more critical than the pharmaceutical industry. A mistaken purchase of a wrongly labelled soap or beverage may cause financial inconvenience. A mistaken dispensing of the wrong medicine can cause death.
It is against this backdrop that the Supreme Court of India, in its landmark judgement of 26th March 2001, laid down a comprehensive set of principles governing the test of deceptive similarity specifically in the context of medicinal products.
The case of Cadila Health Care Ltd versus Cadila Pharmaceuticals Ltd is not merely a trademark dispute between two pharmaceutical giants; it is a seminal contribution to the jurisprudence of intellectual property law in India, one that overruled a previous Supreme Court decision, synthesised decades of Indian and international case law, and set down a framework that courts continue to apply to this day.
The judgement is remarkable for its sensitivity to Indian ground realities, particularly the vast linguistic diversity and widespread illiteracy among the Indian population, and for its insistence that a stricter standard of scrutiny must be applied when the goods in question are medicines rather than ordinary consumer products.
Factual And Procedural Background
The two parties to the dispute, Cadila Health Care Ltd. and Cadila Pharmaceuticals Ltd., were both pharmaceutical companies that had emerged from the restructuring of the erstwhile Cadila Group.
Under the scheme of restructuring approved under Sections 391 and 394 of the Companies Act, 1956, both companies had been permitted to use the name “Cadila” as their corporate name. This shared corporate identity formed the backdrop to a deeper rivalry between the two entities.
Development And Marketing Of “Falcigo”
The appellant, Cadila Health Care Ltd, developed and marketed a drug under the brand name “Falcigo”. This drug contained artesunate and was meant for the treatment of cerebral malaria, specifically the strain known as falciparum malaria, a severe and potentially fatal form of the disease.
- Trade Mark: Falcigo
- Active Ingredient: Artesunate
- Purpose: Treatment of Falciparum Malaria
- Trade Mark Application Date: 20th August 1996
- Class: Part A, Class 5
- Registry: Trade Marks Registry, Ahmedabad
On 20th August 1996, the appellant applied for registration of the trademark “Falcigo” with the Trade Marks Registry at Ahmedabad in Part A, Class 5 under the Trade and Merchandise Marks Act, 1938.
On 7th October 1996, the Drugs Controller General of India granted permission to the appellant to market the drug under this trade mark, and from October 1996 onwards, the appellant claimed to have been manufacturing and selling “Falcigo” across India.
Development And Marketing Of “Falcitab”
The respondent, Cadila Pharmaceuticals Ltd, obtained permission from the Drugs Controller General of India on 10th April 1997 to manufacture a different drug containing Mefloquine Hydrochloride.
This drug was also used for the treatment of Falciparum malaria, but its composition was entirely different from the appellant’s drug.
Crucially, the two drugs had different side effects and were in fact contraindicated in certain respects, meaning that what one drug was suited for, the other may be entirely unsuitable or even harmful.
The respondent chose to sell this drug under the brand name “Falcitab”.
Comparison Of The Two Drugs
| Particulars | Falcigo | Falcitab |
|---|---|---|
| Manufacturer | Cadila Health Care Ltd. | Cadila Pharmaceuticals Ltd. |
| Active Ingredient | Artesunate | Mefloquine Hydrochloride |
| Disease Treated | Falciparum Malaria | Falciparum Malaria |
| Brand Name | Falcigo | Falcitab |
| Nature of Composition | Different | Different |
| Side Effects | Different | Different |
Origin Of The Dispute
In April 1998, the appellant came to know that the respondent had begun selling “Falcitab” in the market.
Alarmed by the similarity between the names “Falcigo” and “Falcitab”, particularly given that both drugs treated the same disease, the appellant filed a suit for injunction in the District Court at Vadodara, seeking to restrain the respondent from using the mark “Falcitab” on the ground that it was deceptively similar to “Falcigo” and was likely to cause confusion and deception among buyers.
Proceedings Before The Lower Courts
Decision Of The Extra Assistant Judge
The Extra Assistant Judge at Vadodara dismissed the application for an interim injunction on 30th May 1998, holding that the two drugs differed in appearance, formulation, and price, and that since both were Schedule L drugs sold exclusively to hospitals and institutions and not across the counter, there was no real chance of deception or confusion.
High Court Decision
The appellant’s appeal to the High Court was also unsuccessful.
The High Court, after examining the packaging and cartoons of both products and surveying various case law, concluded that there was little chance of the two products being confused by an unwary consumer and that passing off one product for the other was not likely.
It was against this order that the appellant approached the Supreme Court by way of a special leave petition.
Litigation Timeline
| Date | Event |
|---|---|
| 20th August 1996 | Application filed for registration of “Falcigo” |
| 7th October 1996 | Permission granted to market “Falcigo” |
| 10th April 1997 | Permission granted to manufacture and market “Falcitab” |
| April 1998 | The appellant learns of respondent’s use of “Falcitab” |
| 30th May 1998 | Interim injunction rejected by Extra Assistant Judge, Vadodara |
| Subsequent Period | Appeal dismissed by the High Court |
| Thereafter | Special Leave Petition filed before the Supreme Court |
The Dispute Before The Supreme Court
The core question before the Supreme Court was whether the brand names “Falcigo” and “Falcitab” were deceptively similar to each other and whether the respondent should be restrained from using the mark “Falcitab”.
But the Court, conscious that the case raised issues of broader significance, chose to go beyond the immediate facts and lay down the governing principles for determining deceptive similarity, especially in relation to pharmaceutical products.
In doing so, the Court also had to grapple with whether the fact that these were Schedule L drugs sold only to hospitals and clinics, and not to the general public over the counter, provided a sufficient safeguard against confusion.
The Court also found it necessary to overrule certain observations made in the more recent decision of S.M. Dyechem Ltd v. Cadbury (India) Ltd, reported as 2000ECR1(SC), which it found to be inconsistent with settled legal principles.
Key Legal Issues Before The Court
- Whether the trade marks “Falcigo” and “Falcitab” were deceptively similar.
- Whether use of “Falcitab” was likely to cause confusion or deception among purchasers.
- Whether a stricter standard should apply when comparing medicinal products.
- Whether Schedule L classification and restricted sale through hospitals eliminated the risk of confusion.
- Whether earlier judicial observations in S.M. Dyechem Ltd. v. Cadbury (India) Ltd. required reconsideration.
- What principles should govern the determination of deceptive similarity in pharmaceutical trademark disputes?
Reasoning and Analysis of the Court
The Supreme Court began by tracing the legal framework governing both registered and unregistered trade marks. Under Section 28 of the Trade and Merchandise Marks Act, 1938, registration in Part A or B of the register confers an exclusive right to use the trade mark. For unregistered marks, Section 27(1) bars proceedings for infringement, but Section 27(2) preserves the right to bring a passing-off action.
Passing off, the Court explained, is grounded in the principle that no person should represent his goods as those of another. The Court referred to Lord Diplock’s formulation in Erwen Warnink BV v. J. Townend and Sons, reported as 1979 (2) AER 927, which identified five elements of the modern tort of passing off: a misrepresentation made by a trader in the course of trade, to prospective customers or ultimate consumers, which is calculated to injure the goodwill of another trader, and which causes or is likely to cause actual damage to that trader’s business or goodwill.
Five Elements of Passing Off
- Misrepresentation by a trader
- Made in the course of trade
- Directed at prospective customers or consumers
- Likely to injure another trader’s goodwill
- Causes or is likely to cause actual damage
The Court then conducted a thorough survey of its own earlier decisions, building towards a holistic and coherent framework.
Survey of Leading Trade Mark Precedents
National Sewing Thread Co. Ltd v. James Chadwick and Bros. Ltd [1953] 4 SCR 1028
In National Sewing Thread Co. Ltd v. James Chadwick and Bros. Ltd, reported as [1953] 4 SCR 1028, the Court had examined Section 8 of the Trade Marks Act, which bars registration of marks likely to deceive or cause confusion. The principle established was that the real question is how an average man of ordinary intelligence would react to a particular trade mark and what association he would form on seeing it.
Corn Products Refining Co. v. Shangrila Food Products Ltd [1960] 1 SCR 968
In Corn Products Refining Co. v. Shangrila Food Products Ltd, reported as [1960]1SCR968, the Court had reinforced that in deciding the question of similarity between two marks, the marks must be considered as a whole, not dissected into component parts. The case involved the marks “Glucovita” and “Gluvita”, and the Court agreed with the minority view that the two marks were similar enough to cause confusion among the Indian public, for whom these English words were essentially foreign and phonetically similar.
Amritdhara Pharmacy v. Satya Deo [1963] 2 SCR 484
In Amritdhara Pharmacy v. Satya Deo, reported as [1963] 2 SCR 484, the Court dealt with the marks “Amritdhara” and “Lakshmandhara” used on similar medicinal preparations. This case became the bedrock of the judgement in the Cadila case.
The court quoted extensively from Amritdhara, where it had been observed that medicines would be purchased by villagers and townsfolk alike, literate and illiterate, and that the question must be approached from the point of view of a man of average intelligence and imperfect recollection. Such a person, the Court reasoned, would not dissect the names etymologically. He would go by the overall structural and phonetic similarity.
It was also observed, drawing on the reasoning of Lord Parker in Re Pianotist Co.’s Application, reported as (1906) 23 RPC 774, that the court must take the two words, judge them both by look and by sound, consider the goods to which they are applied, the nature and kind of customer likely to buy those goods, and all surrounding circumstances.
Durga Dutt Sharma v. N.P. Laboratories [1965] 1 SCR 737
In Durga Dutt Sharma v. N.P. Laboratories, reported as [1965] 1 SCR 737, the Court had drawn the important distinction between an action for passing off and an action for infringement.
| Passing Off | Infringement |
|---|---|
| The use of the plaintiff’s exact trade mark is not necessary. | The defendant must have used the plaintiff’s registered mark or a colourable imitation. |
| The focus is on the likelihood of deception. | The focus is on violation of rights in a registered mark. |
| Protection of goodwill and reputation. | Protection of statutory rights arising from registration. |
Importantly, the court also held that where the similarity between two marks is so close, whether visually, phonetically, or otherwise, that the court concludes there is an imitation, no further evidence is needed to establish that the plaintiff’s rights have been violated.
F. Hoffmann-La Roche and Co. Ltd v. Geoffrey Manner and Co. Pvt. Ltd [1970] 2 SCR 213
In F. Hoffmann-La Roche and Co. Ltd v. Geoffrey Manner and Co. Pvt. Ltd, reported as [1970]2SCR213, the Court had applied both visual and phonetic tests to compare the drug names “Protovit” and “Dropovit” and concluded that they were dissimilar enough to avoid confusion. The judgement had extensively quoted the celebrated test formulated by Lord Parker in Re Pianotist, which had by then become the gold standard for comparing two word marks.
Reconsideration of S.M. Dyechem Ltd. v. Cadbury (India) Ltd.
After building this doctrinal foundation, the Supreme Court turned its critical attention to S.M. Dyechem Ltd. v. Cadbury (India) Ltd., decided in 2000, which had compared the marks “Piknik” and “Picnic” for chocolates.
The Dyechem case had introduced a different approach, suggesting that in cases of composite or device marks, differences in essential features should be given more importance than similarities. It had also suggested that the relevant consumer was one who knew the distinguishing characteristics of the plaintiff’s goods and had sufficient intelligence to tell them apart.
The Supreme Court in the Cadila case firmly rejected both these propositions. It held that the stress in Indian law has always been on common features rather than differences and that the phonetic similarity test, firmly established in Amritdhara, cannot simply be discarded because the marks are written differently.
More critically, the Court found the Dyechem approach to the standard of the relevant consumer to be inconsistent with Indian ground realities. Equating the Indian purchaser with a well-informed and careful English consumer was inappropriate in a country where a large section of the population is illiterate, where multiple languages are spoken, and where English words are essentially foreign sounds.
Accordingly, the Court expressly overruled the decision on merits in Dyechem’s case.
Special Rules for Pharmaceutical Trade Marks
The Court then addressed the specific and weighty issue of pharmaceutical products. It drew extensively on American jurisprudence, noting that even for prescription drugs, confusion in marks can have catastrophic consequences.
American Authorities Relied Upon
| Case | Principle Adopted |
|---|---|
| American Cyanamid Corporation v. Connaught Laboratories Inc. (231 USPQ 128) | Exacting judicial scrutiny is required where medicinal confusion may occur. |
| Blansett Pharmaceuticals Co. v. Carmick Laboratories Inc. (25 USPQ 2nd 1473) | Confusion may occur even for prescription drugs where marks look or sound alike. |
| Glenwood Laboratories Inc. v. American Home Products Corp. (173 USPQ 19) | Confusion between drugs may create harmful medical consequences. |
| R.J. Strasenburgh Co. v. Kenwood Laboratories Inc. (106 USPQ 379) | Healthcare professionals are not immune from mistakes. |
The court also relied on McCarthy on Trademarks for the proposition that physicians and pharmacists, although trained professionals, are not immune from confusion or mistake, particularly where prescriptions are telephoned to pharmacists or where handwriting is illegible.
The court was emphatic on the point that merely because a drug is classified as a Schedule L drug sold only to hospitals and clinics, it does not follow that confusion is impossible. India’s linguistic, urban, semi-urban and rural diversity, combined with the possibility of even accidental negligence by professionals, means that strict measures must be taken to prevent confusion among pharmaceutical marks.
The stakes are simply too high.
The Court quoted from McCarthy on Trademarks that a lesser quantum of proof of confusing similarity should be required when the goods are medicinal products and that if there is any possibility of confusion in the case of medicines, public policy requires that the confusingly similar name be restrained.
Impact of the Drugs and Cosmetics Act, 1940
The Court also took note of Section 17B of the Drugs and Cosmetics Act, 1940, which treats as a spurious drug any drug bearing a name or mark that imitates or resembles another drug in a manner likely to deceive.
Drawing on this provision, the Court directed that before any authority grants permission to manufacture a drug under a brand name, it must satisfy itself that the name will not cause confusion or deception in the market.
The Court suggested that drug regulatory authorities should consider requiring applicants to submit an official search report from the Trademarks Office before approval is granted so that the drug authority can make a properly informed decision.
Factors for Determining Deceptive Similarity
Having surveyed all these principles, the Court synthesised them into a comprehensive list of factors to be considered when determining deceptive similarity in a passing-off action based on an unregistered trademark.
Key Factors Laid Down by the Supreme Court
- The nature of the marks, whether they are word marks, label marks, or composite marks.
- The degree of resemblance between the marks, including phonetic similarity.
- The nature of the goods in respect of which the marks are used.
- The similarity in the nature, character, and performance of the goods of the competing traders.
- The class of purchasers likely to buy the goods, their education and intelligence, and the degree of care they are likely to exercise.
- The mode of purchasing the goods or placing orders.
- Any other surrounding circumstances relevant to the degree of dissimilarity between the competing marks.
The court was careful to note that no fixed weightage can be assigned to any one factor and that each case must be decided on its own facts.
Final Decision of the Court
Despite the elaborate principles laid down, the Supreme Court did not itself decide the question of deceptive similarity between “Falcigo” and “Falcitab” on the merits. The Court took the view that a detailed examination of evidence might be required and that it would not be advisable to express a final opinion at that stage.
Accordingly, the matter was remitted back to the trial court at Vadodara with a direction to decide the suit afresh, keeping in mind all the principles and observations laid down in the judgement. No order as to costs was made. The appeal was accordingly disposed of.
Points of Law Settled in the Case
This judgement settled several significant points of law that have shaped intellectual property jurisprudence in India ever since.
1. Overall Resemblance and Phonetic Similarity
First, it overruled the decision on merits in S.M. Dyechem Ltd v. Cadbury (India) Ltd and reaffirmed that in passing-off actions, the test of similarity focuses on the overall resemblance between marks, with particular emphasis on phonetic similarity, rather than on differences in essential features.
2. Consumer Standard in Indian Conditions
Second, it firmly established that the standard of the relevant consumer in India must be calibrated to Indian conditions, accounting for illiteracy, linguistic diversity, and imperfect recollection, and cannot simply be transplanted from English law.
3. Stricter Standard for Pharmaceutical Products
Third, it held that a stricter standard of deceptive similarity applies to pharmaceutical products, given the potential for serious, even fatal, consequences from confusion between medicines.
4. Hospital and Clinic Sales Not Sufficient Safeguard
Fourth, it held that the fact that a drug is sold only to hospitals and clinics and not over the counter does not by itself provide sufficient protection against confusion, since even trained professionals can make mistakes.
5. Seven-Factor Test for Deceptive Similarity
Fifth, it laid down a comprehensive seven-factor test for assessing deceptive similarity in passing-off actions, which has since become the standard framework applied by Indian courts in trademark disputes.
6. Coordination Between Regulators and Trademark Authorities
Sixth, it flagged the need for coordination between drug regulatory authorities and trade mark offices to prevent confusingly similar names from entering the pharmaceutical market.
Key Legal Principles at a Glance
| Legal Principle | Court’s Finding |
|---|---|
| Passing-Off Test | Focus on overall resemblance and phonetic similarity. |
| Consumer Standard | Must reflect Indian conditions, including linguistic diversity and imperfect recollection. |
| Pharmaceutical Trademarks | Require a stricter standard due to public health implications. |
| Hospital-Only Sales | Not a complete safeguard against confusion. |
| Deceptive Similarity Assessment | Seven-factor test established for passing-off actions. |
| Regulatory Coordination | Need for cooperation between drug authorities and trade mark offices. |
Case Details
| Title | Cadila Health Care Ltd vs. Cadila Pharmaceuticals Ltd. |
|---|---|
| Date of Order | 26th March 2001 |
| Case Number | Appeal (Civil) 2372 of 2001 |
| Citation | AIR 2001 SC 1952; (2001) 5 SCC 73; 2001 (3) SCALE 98; [2001] 2 SCR 743 |
| Name of Court | Supreme Court of India |
| Names of Honourable Judges | Justice Doraiswamy Raju and Justice Brijesh Kumar |
Quick Reference Summary
- Case: Cadila Health Care Ltd. vs. Cadila Pharmaceuticals Ltd.
- Court: Supreme Court of India
- Date: 26th March 2001
- Subject: Passing-Off Action and Deceptive Similarity in Pharmaceutical Trademarks
- Key Holding: Stricter standards apply to pharmaceutical trademarks due to potential public health consequences.
- Significance: Established the landmark framework for determining deceptive similarity in India.
